Sentences with phrase «aids vaccine researchers»

AIDS vaccine researchers say they have some new clues to help focus their search for a safe and effective vaccine against HIV.

Crotty says the ability to measure Tfh cells in the blood will assist AIDS vaccine researchers by serving as an indicator of antibody response.

The maps created by AIDS vaccine researchers currently exploring uncharted immunologic terrain could prove invaluable.

Yet AIDS vaccine researchers have solid reasons to believe they can succeed.

That means, as one AIDS vaccine researcher famously put it more than a decade ago, the field is «flying without a compass.»

Not exact matches

Researchers at Oregon Health & Science University are currently looking for volunteers that can be tested during an upcoming clinical trial for a vaccine that may cure HIV, the virus that causes AIDS.

The stocks are helping the development of new countermeasures such as drugs, vaccines and diagnostics in case smallpox should reappear, and may also allow researchers to explore the impact of smallpox on the human immune system, providing insights into other diseases such as AIDS.

But rather than dashing all hopes for an AIDS vaccine, the trial has heartened some researchers, who see new clues in the battle against the fatal illness.

Ultimately, researchers believe that a T cell — boosting vaccine by itself will not be enough to stave off AIDS.

A major new finding that will significantly advance efforts to create the world's first antibody - based AIDS vaccine was published today by researchers from the La Jolla Institute for Allergy and Immunology.

No data on the vaccine have yet been published and some AIDS researchers have privately expressed fears that the company is moving too fast by testing the vaccine in a developing country.

La Jolla Institute scientist Shane Crotty, Ph.D., a respected vaccine researcher and member of one of the nation's top AIDS vaccine consortiums, showed that certain helper T cells are important for triggering a strong antibody response against HIV, the virus that causes AIDS.

Researchers collected samples and aided in development of an equine vaccine.

The same strategy might aid efforts to design vaccines against other viruses, researchers said.

If AIDS is caused by a virus, why has it been impossible for researchers to develop a vaccine after 20 years and millions of dollars spent?

Researchers led by a team at Duke University identified these immunologic variations by studying blood samples collected from people living with HIV by the NIAID - supported Center for HIV / AIDS Vaccine Immunology (CHAVI).

LONDON (Reuters)-- Researchers announced the launch of two big studies in Africa on Thursday to test a new HIV vaccine and a long - acting injectable drug, fuelling hopes for better ways to protect against the virus that causes AIDS.

Two decades ago, researchers imagined that a vaccine would end AIDS.

Of more than 50 therapeutic vaccine trials so far, this is the first one that has bolstered the immune system in a «meaningful» way, says Steven Deeks, an HIV / AIDS clinician and researcher at the University of California, San Francisco, who is «cautiously optimistic» that the data will inspire others to study the approach.

But when a field suffers as much failure as the search for an AIDS vaccine has over the past 30 years, researchers sometimes celebrate glimpses of hope.

HIV is finally revealing its weak spots to researchers, bringing an effective vaccine against AIDS closer to reality.

For 30 years, researchers have struggled to determine which immune responses best foil HIV, information that has guided the design of AIDS vaccines and other prevention approaches.

Although no vaccine against HIV exists, advances in prevention and treatment have led to a growing conviction among researchers, public health officials, and politicians that the HIV / AIDS epidemic can be brought to a halt with existing tools.

In the real world, a field like the AIDS vaccine one has so much failure that when researchers see positive data they say, Eureka!

The fog around the largest AIDS vaccine study ever conducted began to lift today, as Thai and U.S. researchers for the first time publicly presented a detailed analysis of their data to over 1000 scientists gathered here at an annual meeting.

The row over the Thai trials has been fuelled by an explosive mix of factors, including the pace at which the HIV epidemic is growing in Asia, the future of the vaccines industry, and domestic tensions in the US between AIDS researchers, activists and politicians.

AIDS researcher Jay Levy at the University of California at San Francisco finds the results encouraging, but notes that the vaccines seemed to have no effect on the amount of virus in the bloodstream of people who contracted HIV during the study.

The Viral Bioinformatics Resource Center project complements the strengths in viral genomics, pathogenesis and vaccine production at JCVI and is an essential aid to researchers tackling the new and emerging biological threats the world faces today,» said Scheuermann.

In the new issue of IAVI Report we wrote about how researchers at the AIDS Vaccine 2010 conference in Atlanta discussed the limited window of opportunity for conducting clinical trials to test partially effective HIV prevention strategies, including HIV vaccine candidates and oral or topical antiretroviral pre-exposure prophylaxis (PrEP), in combiVaccine 2010 conference in Atlanta discussed the limited window of opportunity for conducting clinical trials to test partially effective HIV prevention strategies, including HIV vaccine candidates and oral or topical antiretroviral pre-exposure prophylaxis (PrEP), in combivaccine candidates and oral or topical antiretroviral pre-exposure prophylaxis (PrEP), in combination.

Nearly 35 years after HIV, the virus that causes AIDS, was discovered, researchers at UNLV continue to forge ahead in the quest for prevention, education and a possible vaccine or cure.

«After two years of analyzing the results of the largest AIDS vaccine clinical trial ever held — called RV144 — researchers say they have found two ways the immune system can respond, which could predict whether those inoculated will be protected or are more likely to become infected with HIV.»

At the first plenary session of AIDS Vaccine 2011, which opened this morning in Bangkok, Thailand, researchers presented the results of a two - year - long effort to try to identify an immunological explanation for the modest 31 % efficacy afforded by the prime - boost vaccine regimen tested in the RV144 trial, the first to show any efficacy in protecting against HIV infVaccine 2011, which opened this morning in Bangkok, Thailand, researchers presented the results of a two - year - long effort to try to identify an immunological explanation for the modest 31 % efficacy afforded by the prime - boost vaccine regimen tested in the RV144 trial, the first to show any efficacy in protecting against HIV infvaccine regimen tested in the RV144 trial, the first to show any efficacy in protecting against HIV infection.